A new class of anti-cancer drugs: HDAC-inhibitors.
Pelicci
Pier Giuseppe
PG
European Institute of Oncology, Department of Experimental Oncology, Milan, Italy.
D000123:Acetyltransferases / Q000037:antagonists & inhibitors*; D000208:Acute Disease; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D051548:Histone Acetyltransferases; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000201:enzymology; D029701:Saccharomyces cerevisiae Proteins / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D029701:Saccharomyces cerevisiae Proteins; D000123:Acetyltransferases; D051548:Histone Acetyltransferases